Jones Day
8 Contributors
5 Contributions by Jones Day Experts
PRACTICE NOTES
What is Alternative Dispute Resolution?
Alternative Dispute Resolution (ADR) is an umbrella label for methods that settle disputes without resorting to litigation. ADR is increasingly chosen to address life sciences conflicts. This Practice Note will set out the key benefits and limitations of different ADR models for disputes arising in this field and offer practical guidance on making the most of each route. For broader guidance on ADR, as well as a detailed comparison of processes, see Practice Note: What is ADR?
The advantages of ADR for life sciences disputes
Life sciences disputes are diverse and often turn on complex, highly technical topics. Even so, several recurring characteristics mean ADR can be well-suited in the right circumstances.
Disputes are multi-jurisdictional
The life sciences industry frequently involves cross-border collaborations, with participants across Asia, Europe and North America. Clashes may emerge from differing corporate cultures and/or divergent legal systems. For these
Life Sciences
PRACTICE NOTES
General Data Protection Regulation (EU GDPR) and UK GDPR
The General Data Protection Regulation, Regulation (EU) 2016/679 (EU GDPR), became enforceable across the EEA (which then included the UK) on 25 May 2018. Life sciences organisations frequently collect and/or process substantial amounts of personal information, including health-related data, about individuals (or ‘data subjects’) such as patients and clinical trial participants. As a result, the relevance of the EU GDPR and the United Kingdom General Data Protection Regulation, Assimilated Regulation (EU) 2016/679 (UK GDPR) (which applies after the UK’s withdrawal from the EU) for life sciences companies cannot be underestimated.
Assimilated law is the term used for retained EU law (REUL) that remains operative after the end of 2023. The reclassification of REUL (and related terminology) as assimilated law marks a change in its status and handling under UK law, in that it is
Life Sciences
PRACTICE NOTES
The General Data Protection Regulation, Regulation (EU) 2016/679 (EU GDPR)
The General Data Protection Regulation (Regulation (EU) 2016/679, the EU GDPR) has applied across the EEA since 25 May 2018. Organisations in the life sciences gather and/or handle volumes of personal information, including health data, relating to individuals (the ‘data subjects’), notably patients and participants in clinical trials. As such, the relevance of the EU GDPR to life sciences businesses is considerable. This Practice Note outlines elements within the EU GDPR framework that have a direct bearing on life sciences companies and their operations. It is not an exhaustive treatment of the EU GDPR and should be read alongside the following Practice Notes: Data protection principles; Processing personal data—standard of consent; and Processing personal data—obtaining, recording and managing consent. For further detail on how clinical trials interface with data protection rules, see Practice Note:
EU Law
PRACTICE NOTES
ARCHIVED: This content was published in 2020 and is not maintained. The Market Standards trend report delivers detailed analysis of the 12 binding offers and ten potential offers made for Main Market and AIM companies subject to the Takeover Code in H1 2020. It also provides insight into public M&A patterns and what we might anticipate in H2 2020 and beyond.
What does the Market Standards trend report cover?
deal value and volume
private equity deal activity
UK and foreign bidder activity
industry focus
deal structures
post-offer statements of intention
shareholder activism
coronavirus (COVID-19) issues and impact
legal and regulatory developments
What are the highlights from the report?
The economic uncertainty arising from the coronavirus (COVID-19) pandemic has had a material effect on public M&A activity, with activity notably lower in Q2 2020. In H1 2020 there were 12 firm offers announced, compared with 33 firm offers in H1 2019 and 33 firm...
Corporate
PRACTICE NOTES
ARCHIVED: This content was published in 2020 and is not maintained.
The Market Standards trend report presents detailed examination of the 66 firm offers and 45 possible offers made for quoted companies governed by the Takeover Code during 2019. It also shares insight into public M&A patterns and what we might expect in 2020 and thereafter.
What does the Market Standards trend report cover?
transaction value and volume
private equity participation
hostile takeovers and rival bids
sector focus
UK and overseas bidder activity
shareholder activism
post-offer undertakings and national security undertakings
legal and regulatory developments
The report assesses headline transactions, including the Takeaway.com/Prosus competing bids for Just Eat, Advent International’s £4bn offer for Cobham, the £2.6bn consortium bid for Inmarsat, and Non-Standard Finance’s £1.3bn hostile approach for Provident Financial.
What are the highlights from the
Corporate
If you expected to see yourself on this page, click here.
